930-62-1

Basic information

• Product Name: 2,4-Dimethylimidazole
• Synonyms: TIMTEC-BB SBB004378;2,4-DIMETHYLIMIDAZOLE;2,4-DIMETHYL-1H-IMIDAZOLE;2,4-dimethyl;2,4-Dimethylimidazole,97%;2,4-Dimethylimidazole, tech., 90%;1H-Imidazole, 2,4-dimethyl-;2,4-Dimethylimidazole,90%, tech.
• CAS NO: 930-62-1
• Molecular Formula: C₅H₈N₂
• Molecular Weight: 96.13
• EINECS: 213-221-4
• Product Categories: Imidazoles, Pyrroles, Pyrazoles, Pyrrolidines;pharmacetical;Imidazoles;Imidaxoles
• Mol File: 930-62-1.mol

Chemical Properties

• Melting Point: 85-87 °C
• Boiling Point: 266 °C (733 mmHg)
• Flash Point: 266°C/733mm
• Appearance: Yellow to orange/Weak Mass or Viscous Liquid
• Density: 0.9678 (rough estimate)
• Vapor Pressure: 0.00945mmHg at 25°C
• Refractive Index: 1.5000 (estimate)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.36(at 25℃)
• Water Solubility: Soluble in water.
• BRN: 1639
• CAS DataBase Reference: 2,4-Dimethylimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dimethylimidazole(930-62-1)
• EPA Substance Registry System: 2,4-Dimethylimidazole(930-62-1)

Safety Data

• Hazard Codes: C
• Statements: 34-22
• Safety Statements: 45-36/37/39-26
• RIDADR: 3263
• RTECS: NI4839712
• HazardClass: 8
• PackingGroup: Ⅲ
• Hazardous Substances Data: 930-62-1(Hazardous Substances Data)

Usage

Uses

Used in Epoxy Resin Industry:
2,4-Dimethylimidazole is used as a curing agent for epoxy resins, enhancing their bonding, coating, and encapsulation properties.
Used in Composite Materials Industry:
2,4-Dimethylimidazole is used as a component in composite materials, contributing to their overall performance and properties.
Used in Medical Industry:
2,4-Dimethylimidazole is employed as a medical raw material, utilized in the development and production of pharmaceuticals.
Used in Organic Synthesis:
2,4-Dimethylimidazole is used in organic synthesis processes, serving as a versatile intermediate for the creation of various organic compounds.

Synthesis Reference(s)

Tetrahedron Letters, 12, p. 2205, 1971 DOI: 10.1016/S0040-4039(01)96820-0

InChI:InChI=1/C5H8N2/c1-4-3-6-5(2)7-4/h3H,1-2H3,(H,6,7)

Upstream product

• 75-07-0 acetaldehyde 
• 78-98-8 2-oxopropanal 
• 930-61-0 2,4-dimethyl-2-imidazoline 
• 67-66-3 chloroform 
• 3615-41-6 L-Rhamnose 
• 83576-16-3 1-(2-hydroxypropyl)-5-methyltetrazole 
• 83505-97-9 2,5-dimethylimidazole-1-carbonitrile 
• 64-19-7 acetic acid 
• 78-90-0 1,2-diaminopropan 
• 93742-53-1 trans-5-methyl-1-(prop-1-enyl)tetrazole 
• 83505-98-0 2-azido-3,6-dimethylpyrazine 
• 52726-31-5 2,4-dimethyl-1-(phenylmethyl)-1H-imidazole 
• 96-26-4 dihydroxyacetone 
• 50-00-0 formaldehyd 

Downstream Products

• 4472-45-1 4-chloro-2,6-dimethylpyrimidine 
• 95-89-6 2,5-dimethyl-3-chloropyrazine 
• 38557-72-1 2-chloro-3,5-dimethylpyrazine 
• 75712-73-1 5-Chloro-2,4-dimethylpyrimidine 
• 75712-74-2 4-chloro-2,5-dimethylpyrimidine 
• 102792-10-9 2,4-Dimethyl-1-(3-methyl-4-nitrophenyl)imidazole 
• 131885-68-2 5-(2,4-Dimethyl-imidazol-1-yl)-2-nitro-phenylamine 
• 131885-59-1 5-(2,4-Dimethyl-imidazol-1-yl)-4-methyl-2-nitro-phenylamine 
• 102792-15-4 1-(4-nitro-3-trifluoromethylphenyl)-2,4-dimethylimidazole 
• 131885-56-8 5-(2,4-Dimethyl-imidazol-1-yl)-3-methyl-2-nitro-phenylamine 
• 23309-18-4 2,4-dimethyl-1-(4-nitrophenyl)-1H-imidazole 
• 108857-31-4 ethyl N-(trifluoroacetyl)-N-<<2-nitro-5-(2,4-dimethylimidazol-1-yl)phenyl>methyl>glycinate 
• 56536-44-8 1H-5-Acetyl-2,4-dimethylimidazole 
• 677704-68-6 4-(2,4-dimethyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzonitrile 

Relevant articles and documents

Deprotection of N-benzylbenzimidazoles and N-benzylimidazoles with triethylsilane and Pd/C

The benzyl group is a protecting group for benzimidazoles and imidazoles that can survive acidic, basic, oxidizing, and reducing conditions. Deprotection, however, can require vigorous and potentially non-chemoselective methods. The triethylsilane–Pd/C reduction system is an exceptionally mild, convenient, and efficient method for deprotecting N-benzylbenzimidazoles that are unsubstituted at the 2- and 4-positions as well as suitably substituted N-benzylimidazoles.

Non-enzymatic large scale synthesis of RNA

This invention pertains to the development of methods that accomplish efficient, non-enzymatic, nucleic acid-directed (e.g. RNA-directed) nucleic acid (e.g. RNA) synthesis. In certain embodiments the methods provide conditions that favor oligouridylate synthesis with excellent yield and, at least, up to 30% regioselectivity favoring the RNA linkage. The methods preferably involve contacting, in the presence of lead ions (Pb2+) and/or tin ions (Sn2+) and, optionally, magnesium ions (Mg2+), a template nucleic acid with a nucleotide derivatized with an imidazolide.

Color developing agent, processing composition and color image-forming method

A method for forming a color image comprises the step of developing an image-wise exposed silver halide color photographic photosensitive material at the presence of a 6-aminotetrahydroquinoline color developing agent which is the following compound or its analoge. According to this method, the rapid process can be attained and an image of a low fog density can be obtained. STR1

Tetrasubstituted imidazoles

A compound of the formula STR1 wherein the substituents are defined in the specification useful for the treatment of cardiovascular disorders.

Method of preventing abnormal stimulation of AT1 and AT2 receptors

Products of formula (1), wherein R1 is particularly STR1 alkyl, alkylthio or alkoxy; R2 is particularly halogen, --S--R, --O--R or --C(OH)(R)--COOH, where R is alkyl or alkenyl; R3 is particularly carboxy, acyl, halogen, alkyl, alkenyl or alkylthio; and R4 is particularly --(CH2)m1 --COOR4, --(CH2)m1 --CONHR14, --(CH2)m1 --CN, --SO2 --NH--SO2 --R14, 13 NH--SO2 --R14, --PO3 R14, or --NH--SO2 --CF3, where m1 is 0-4 and R14 is hydrogen, alkyl or alkenyl; are useful for preparing pharmaceutical compositions for treating disorders resulting from abnormal stimulation of angiotensin II receptors AT1 and AT2.

CATALYTIC SYNTHESIS OF C-ALKYLIMIDAZOLES OVER PLATINUM-ALUMINA CATALYSTS

The synthesis of C-alkylimidazoles from 1,2-diamines and carboxylic acids over bifunctional platinum-alumina catalysts has been studied.It has been shown that this method is effective for the synthesis of 2-alkyl and 2,4-dialkylimidazoles including imidazoles with long-chain alkyls.The effect of the reaction temperature, space velocity of the flow of the raw materials, and dilution by hydrogen on the yield of product has been examined for the example of the synthesis of 2-methylimidazole from ethylenediamine and acetic acid, and the stability of the catalyst in continuous reaction cycles with intermediate oxidative regeneration has been studied.The composition of the accompanying products has been established and a mechanism proposed for their formation.Keywords: bifunctional catalyst, platinum-alumina catalyst, alkylimidazoles, 2-methylimidazole.

Synthesis of Imidazoles from Alkenes

Alkenes are converted into imidazoles through their epoxides by a sequence involving ring-opening with readily available 2-tributylstannyltetrazoles (8), dehydration of the resulting alcohols (9) using methyltriphenoxyphosphonium iodide in a improved procedure to give 1-alkenyltetrazoles (12), which give imidazoles (17) on photolysis.

Synthesis of Some Alkyl- and Arylimidazoles

The pyrolysis of 2-azidopyrazines led to give 1-cyanoimidazoles, which were hydrolyzed in alkaline and acidic media to the corresponding imidazoles.This ring transformation occured also by photolysis.

Preparation of 4-methylimidazoles

A process for the preparation of 4-methylimidazoles by reacting methylglyoxal with ammonia and an aldehyde in aqueous solution, wherein the reaction is carried out at a pH of above 7 and either the reactants are all brought into contact simultaneously or the aldehyde and the methylglyoxal are added simultaneously to the aqueous ammonia solution.

A New Synthesis of Imidazoles

Alkenes are converted into imidazoles through their epoxides by treatment with 2-tri-n-butylstannyltetrazoles (2), followed by dehydration with methyltriphenoxyphosphonium iodide in an improved procedure, and photolysis of the resulting vinyltetrazoles (4).